---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-24-000049"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:15:01.945295+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna outlines 10 product approvals by 2027; cuts R&D spend, issues 2025 revenue guidance $2.5-3.5B

## Summary
- Expects ten product approvals through 2027, including three respiratory vaccine submissions in 2024 (next-gen COVID, flu/COVID combo, RSV for high-risk adults).
- Positive Phase 3 results for RSV vaccine in high-risk adults 18-59; sBLA filing planned in 2024 using Priority Review Voucher.
- Cuts cumulative R&D spend for 2025-2028 by 20% to $16B; 2025 R&D guidance $4.2-4.5B; 2025 revenue guidance $2.5-3.5B.
- Norovirus vaccine mRNA-1403 advances to Phase 3; INT melanoma Phase 3 substantially enrolled but FDA not supportive of accelerated approval.
- Five pipeline programs discontinued; plans to break even on operating cash cost basis in 2028 with $6B revenue.

## SEC filing metadata
- accession: 0001682852-24-000049
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000049/0001682852-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000049/mrna-20240912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-24-000049
- JSON: https://secwatch.observer/filing/0001682852-24-000049.json
- Plain text: https://secwatch.observer/filing/0001682852-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.